Synthesis of Unsymmetrical Diarylureas via Pd-Catalyzed C–N Cross-Coupling Reactions
摘要:
A facile synthesis of unsymmetrical N,N'-diarylureas is described. The utilization of the Pd-catalyzed arylation of ureas enables the synthesis of an array of diarylureas in good to excellent yields from benzylurea via a one-pot arylation-deprotection protocol, followed by a second arylation.
[EN] DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ENRICHIS EN DEUTÉRIUM EN TANT QU'INHIBITEURS DE KINASES
申请人:ASCEPION PHARMACEUTICALS INC
公开号:WO2012028106A1
公开(公告)日:2012-03-08
The present invention provides deuterium-enriched heteroaryl-containing urea compounds (I) and use of the same for treating conditions mediated by protein kinase such as
In continuation of our research to explore new antiproliferative agents, we report herein the synthesis and antiproliferative activity of two new series of N-(substituted phenyl)-5-aryl-1,3,4-oxadiazol-2-amine (4a–j) and N-[5-aryl-1,3,4-oxadiazol-2-yl]methyl}-substituted aniline (4k–t) analogs. The antiproliferative activity of fifteen compounds (4a–h, and 4n) was tested against nine different panels
Phenylureas. Part 1. Mechanism of the basic hydrolysis of phenylureas
作者:Robert Laudien、Rolf Mitzner
DOI:10.1039/b008532o
日期:2001.11.1
The mechanism of the hydrolytic decomposition of phenylureas in basic media in the pH range 12 to 14 is investigated. In this pH range a levelling of the rate–pH curve is observed as well as a change of the substituent influence on the hydrolysis rate. These experimental findings suggest the formation of an unreactive side product of the phenylurea in a parasitic side equilibrium at sufficiently high pH. The urea dissociates at the aryl–NH group to give its conjugate base. For the hydrolytic decomposition of phenylureas an addition–elimination mechanism is proposed as has been established for the alkaline hydrolysis of carboxylic acid esters and amides.
Compounds of formula (I), and pharmaceutically acceptable salts thereof:
wherein
L is NH or O;
X is a moiety capable of hydrogen bonding to the NH group depicted in formula (I);
R₁ and R₂ are independently selected from hydrogen, halogen, CF₃, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C1-7 acyl, C1-7 acylamino, C1-6 alkylsulphonylamino, N-(C1-6 alkylsulphonyl)-N-C1-4 alkylamino, C1-6 alkylsulphinyl, carboxy, C1-6 alkoxycarbonyl, hydroxy, nitro or amino, aminocarbonyl, aminosulphonyl, aminosulphonylamino or N-(aminosulphonyl)-C1-4 alkylamino optionally N-substituted by one or two groups selected from C1-6 alkyl, C3-8 cycloalkyl, C3-8 cycloalkyl C1-4 alkyl, phenyl or phenyl C1-4 alkyl groups or optionally N-disubstituted oy C4-5 polymethylene; and
Z is a group of formula (a), (b) or (c)
wherein n is 2 or 3; p is l or 2; q is l to 3; r is l to 3: and
R₃ or R₄ is C1-7 alkyl, C3-8 cycloalkyl, C3-8 cycloalkyl-C1-2 alkyl or C2-7 alkenyl-C1-4 alkyl; having 5-HT M-receptor antagonist activity, a process for their preparation and their use as pharmaceuticals.
式 (I) 的化合物及其药学上可接受的盐类:
其中
L 是 NH 或 O;
X 是能与式 (I) 所示 NH 基团氢键结合的分子;
R₁ 和 R₂ 独立选自氢、卤素、CF₃、C1-6 烷基、C1-6 烷氧基、C1-6 烷硫基、C1-7 丙烯酸基、C1-7 丙烯酸氨基、C1-6 烷基磺酰基氨基、N-(C1-6 烷基磺酰基)-N-C1-4 烷基氨基、C1-6 烷基亚磺酰基、羧基、C1-6 烷氧羰基、羟基、硝基或氨基、氨羰基、氨磺酰基、氨磺酰氨基或 N-(氨磺酰基)-C1-4烷基氨基,可任选被选自 C1-6 烷基、C3-8 环烷基、C3-8 环烷基 C1-4 烷基、苯基或苯基 C1-4 烷基的一个或两个基团或任选被 N-二取代的 oy C4-5 聚亚甲基取代;和
Z 是式(a)、(b)或(c)的基团
其中 n 是 2 或 3;p 是 l 或 2;q 是 l 至 3;r 是 l 至 3:以及
R₃ 或 R₄ 是 C1-7 烷基、C3-8 环烷基、C3-8 环烷基-C1-2 烷基或 C2-7 烯基-C1-4 烷基;具有 5-HT M-受体拮抗剂活性、其制备方法和药物用途。
Bhatia, Sandeep; Yusuf, Mohammad; Garg, Shiv Kumar, Indian Journal of Heterocyclic Chemistry, <hi>2022</hi>, vol. 32, # 2, p. 209 - 216